SPRUCE STREET CAPITAL LP
Q2 2026 Form 13-F

NEW YORK, DELAWARE
CIK 0002050194 · CRD 333213 · SEC-registered investment adviser
$509.7M Reported Value Total

SPRUCE STREET CAPITAL LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $555,900,000, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
3 funds · $900.9M gross asset value
Hedge Fund: $900.9M
Source: Form ADV filed 2026-03-02
Reported value
$509.7M
Quarter over quarter
+19.9%
Holdings
30
Top-10 concentration
70.2%

Key People

Form ADV owners & control persons
Simon Basseyn
MANAGING MEMBER
Alex Ryan Rosen
MANAGING MEMBER
Stephen Leslie Cohen
CHIEF COMPLIANCE OFFICER AND CHIEF OPERATING OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2026 13F record

Q2 2026 13F filing summary

Q2 2026 Form 13F portfolio summary
Period of report June 30, 2026
Filed August 13, 2026
Form 13F-HR
Reported value $509.7M
Positions 30
Change in reported value +22.5%
New positions 5
Exited positions 3
Position turnover 24.2%
Top-10 concentration 70.2%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 13, 2026
39 $629.0M
Q2 2026 13F
Filed Aug 13, 2026
30 $509.7M
Q1 2026 13F
Filed May 14, 2026
28 $415.9M
Q4 2025 13F
Filed Feb 13, 2026
27 $302.7M

Top 20 holdings · Q2 2026

Largest Q2 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 KNSA KINIKSA PHARMACEUTICALS INTL $58.7M 11.52%
2 RLAY RELAY THERAPEUTICS INC $55.8M 10.95%
3 LBRX LB PHARMACEUTICALS INC $44.7M 8.76%
4 RLMD RELMADA THERAPEUTICS INC $44.2M 8.68%
5 ANRO ALTO NEUROSCIENCE INC $35.7M 7.01%
6 DNTH DIANTHUS THERAPEUTICS INC $34.6M 6.79%
7 ALKS ALKERMES PLC $28.5M 5.59%
8 SVRA SAVARA INC $21.3M 4.17%
9 PCVX VAXCYTE INC $17.8M 3.49%
10 ELVN ENLIVEN THERAPEUTICS INC $16.7M 3.28%
11 ENTA ENANTA PHARMACEUTICALS INC $15.9M 3.11%
12 CATX PERSPECTIVE THERAPEUTICS INC $12.6M 2.47%
13 IFRX INFLARX NV $12.0M 2.35%
14 SRZN SURROZEN INC $11.2M 2.2%
15 ALMS ALUMIS INC $11.0M 2.17%
16 IPSC CENTURY THERAPEUTICS INC $9.9M 1.95%
17 NERV MINERVA NEUROSCIENCES INC $9.2M 1.8%
18 SABS SAB BIOTHERAPEUTICS INC $8.6M 1.68%
19 ANTX AN2 THERAPEUTICS INC $8.0M 1.58%
20 ERAS ERASCA INC $7.7M 1.52%

Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings